Claire Harrison
Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.
Overview
Claire Harrison was principal investigator of COMFORT-II, the European trial showing the JAK inhibitor ruxolitinib shrinks spleens and improves symptoms compared with best available therapy in myelofibrosis, which with COMFORT-I made ruxolitinib the first approved MPN therapy. She has led the MAJIC, PT-1 and RESPONSE trials in polycythaemia vera and essential thrombocythaemia and chairs the UK MPN research network.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
Pages like this
not linked directly; found by shared links- ProductPacritinib
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
- ProductMomelotinib
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
- ProductFedratinib
Shares COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
- ProductRuxolitinib
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
- TargetJAK2
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
- PersonPeter Hillmen
Shares Small-molecule kinase inhibitors and the tag uk.
- CompanyIncyte
Shares COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetMDM2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.